AMENDMENT TO THE RESEARCH COLLABORATION AND LICENSE AGREEMENTResearch Collaboration and License Agreement • May 8th, 2015 • Alnylam Pharmaceuticals, Inc. • Pharmaceutical preparations • Massachusetts
This Amendment to the Research Collaboration and License Agreement (this “Amendment”) is entered into as of February 27, 2015, by and between Novartis Institutes for BioMedical Research, Inc., a corporation organized and existing under the laws of Delaware, with its principal place of business at 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, and Alnylam Pharmaceuticals, Inc., a corporation organized and existing under the laws of Delaware, with its principal place of business at 300 Third Street, 3rd Floor, Cambridge, Massachusetts 02142.
SECOND AMENDED AND RESTATED STRATEGIC COLLABORATION AND LICENSE AGREEMENTStrategic Collaboration And • May 8th, 2015 • Alnylam Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
This Second Amended and Restated Strategic Collaboration and License Agreement (the “Agreement”) is executed this January 8, 2015 (the “Second Restatement Date”), between Isis Pharmaceuticals, Inc., a Delaware corporation having an address at 2855 Gazelle Court, Carlsbad, CA 92010 (“Isis”) and Alnylam Pharmaceuticals, Inc., a Delaware corporation having an address at 300 Third Street, Cambridge, MA 02142 (“Alnylam”). Isis and Alnylam may be referred to herein as the “Parties,” or each individually as a “Party.”
